• AcouSort published its annual report for 2025, highlighting stronger commercial momentum as it pushed its acoustofluidic sample-preparation technology toward broader OEM adoption in diagnostics, cell therapy, and lab automation.
• Business activity centered on expanding evaluation and integration projects, including a technology evaluation agreement with SeeQ Diagnostics for automated blood sample preparation.
• In cell therapy, the group broadened industry engagement through collaborations with MFX and Bio-Recell, positioning projects as potential pipelines into longer-term OEM supply agreements.
• Sales traction was supported by repeat orders tied to diagnostic prototyping with Moeller Medical, alongside additional AcouWash system placements with industry and academic users.
• Management framed 2026 as a transition year aimed at converting feasibility studies into recurring OEM agreements, supported by an amended Werfen license deal that brings forward prepaid minimum royalties totaling about USD 1.3 million in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcouSort AB published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.